The results demonstrated that the TBILA/AGAP2-AS1/Cyfra21-1 combination displayed a high AUC value (0.853, Table 5, Fig. 6A) in distinguishing all NSCLC patients from healthy controls. Here, AGAP2 is linked to non-small cell lung carcinoma.